Persistent Placoid Maculopathy: Prognosis Factors and Functional Outcomes.
Pierre GasconFrederic MatontiMarie BeylerianAudrey FeldmanAlban CometBenjamin DonnadieuOlivier LoriaDaniele DenisLaurent KodjikianThibaud MathisPublished in: Ocular immunology and inflammation (2019)
Purpose: To identify prognosis factors and functional outcomes of persistent placoid maculopathy (PPM). Methods: We collected personal PPM cases and combined them with the data from the literature. Results: 68 eyes of 37 patients with PPM were analyzed, including six new cases. Twenty-six patients were men (70%) with a mean age of 51.8 years old. The mean initial visual acuity (VA) was 0.52 LogMar ± 0.55 for a mean final VA of 0.49 LogMar ± 0.51. Risk factors for poor VA included: initial VA less than 0.2 LogMar (p < .0001), cardiovascular risk factor (p = .008), autoimmune-related and/or systemic pro-inflammatory conditions (p = .003), choroidal neovascularization (p = .001), macular atrophy (p = .03) and absence of systemic corticosteroid treatment (p = .03). Conclusion: PPM is a choroidal inflammation. Identifying prognosis factors may help to guide treatment and follow-up. We showed that anti-inflammatory drugs, and anti-VEGF injections in cases of choroidal neovascularization, may lead to better outcomes.
Keyphrases
- optical coherence tomography
- diabetic retinopathy
- vascular endothelial growth factor
- end stage renal disease
- age related macular degeneration
- chronic kidney disease
- systematic review
- risk factors
- newly diagnosed
- ejection fraction
- type diabetes
- prognostic factors
- combination therapy
- optic nerve
- endothelial cells
- machine learning
- skeletal muscle
- platelet rich plasma
- artificial intelligence
- weight loss